^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    relacorilant (CORT125134)

    i
    Other names: CORT125134, CORT-125134, CORT 125134
    Company:
    Corcept Therap
    Drug class:
    GCR antagonist
    Related drugs:
    2d
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • relacorilant (CORT125134)
    1m
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    7ms
    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=178, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    7ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    8ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    10ms
    IRB22-1318: A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, University of Chicago | Trial completion date: Apr 2029 --> Apr 2028 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • relacorilant (CORT125134)
    12ms
    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Corcept Therapeutics | Enrolling by invitation --> Active, not recruiting | N=75 --> 125
    Enrollment closed • Enrollment change
    |
    relacorilant (CORT125134)
    1year
    GRADIENT: Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (clinicaltrials.gov)
    P3, N=137, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    relacorilant (CORT125134)
    1year
    New Trends in Treating Cushing's Disease. (PubMed, touchREV Endocrinol)
    At the pituitary level, pasireotide is an approved somatostatin receptor ligand, and compounds targeting cell cycle regulation, cell signalling and epigenetics are now under investigation. Levoketoconazole and osilodrostat are novel steroid inhibitors, and relacorilant overcomes the adverse effects of mifepristone. Adrenal ACTH receptor blockage and immunotherapy could also play a role.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    relacorilant (CORT125134) • Signifor (pasireotide) • Mifeprex (mifepristone)
    over1year
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=360, Active, not recruiting, Corcept Therapeutics | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)